Kiromic BioPharma, Inc. (KRBP)

OTCMKTS: KRBP · Delayed Price · USD
0.340
-0.045 (-11.69%)
Sep 25, 2023, 1:26 PM EDT - Market closed
Market Cap 399.93K
Revenue (ttm) n/a
Net Income (ttm) -35.41M
Shares Out 1.18M
EPS (ttm) -55.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 10,722
Open 0.403
Previous Close 0.385
Day's Range 0.290 - 0.415
52-Week Range 0.290 - 15.300
Beta 0.16
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2023

About KRBP

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Employees 31
Stock Exchange OTCMKTS
Ticker Symbol KRBP
Full Company Profile

Financial Performance

Financial Statements

News

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14

HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial in...

12 days ago - Business Wire

Kiromic BioPharma Welcomes Two New Directors to its Board

HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artific...

2 months ago - Business Wire

Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer.

5 months ago - Business Wire

Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® ...

6 months ago - Business Wire

Kiromic BioPharma Announces Reverse Stock Split

HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artifici...

7 months ago - Business Wire

Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc.

7 months ago - Business Wire

Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® ...

7 months ago - Business Wire

Kiromic BioPharma CEO Issues Letter to Stockholders

HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artifici...

7 months ago - Business Wire

SHAREHOLDER ALERT: Kiromic Biopharma, Inc. (KRBP) Officers and Directors Under Investigation for Possible False Statements About Its Commercial Prospects

SAN FRANCISCO , Nov. 8, 2022 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Kiromic Biopharma, Inc. (NASDAQ: KRBP) relating to...

11 months ago - PRNewsWire

Kiromic BioPharma Arranges Up to $10 Million Financing

HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artifici...

11 months ago - Business Wire

Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy

HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® ...

1 year ago - Business Wire

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Kiromic BioPharma (KRBP) Investors with Losses to Lead Plaintiff Deadline in Securities Class Action

San Francisco, California--(Newsfile Corp. - October 4, 2022) - Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now.Relevant Per...

1 year ago - Newsfile Corp

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - October 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPhar...

1 year ago - Newsfile Corp

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders

NEW YORK , Oct. 4, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the ...

1 year ago - PRNewsWire

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. With Losses of $75,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 3, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Ki...

1 year ago - Accesswire

KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

New York, New York--(Newsfile Corp. - October 3, 2022) - Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities la...

1 year ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP

NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP).  Such investors are advised ...

1 year ago - PRNewsWire

KRBP FINAL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP

New York, New York--(Newsfile Corp. - October 3, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kiromic BioPharma, Inc.

1 year ago - Newsfile Corp

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - October 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPhar...

1 year ago - Newsfile Corp

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Kiromic Investors of a Lead Plaintiff Deadline of October 4, 2022

NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Attention Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on...

1 year ago - PRNewsWire

KRBP Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action Lawsuit

RADNOR, Pa. , Oct. 2, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic Bio...

1 year ago - PRNewsWire

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm's Attorneys Before Oct. 4th Application Deadline in Securities Class Action

San Francisco, California--(Newsfile Corp. - October 1, 2022) - Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now. Class Perio...

1 year ago - Newsfile Corp

KRBP TUESDAY DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors With Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP

NEW YORK , Sept. 30, 2022 /PRNewswire/ -- WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kiromic BioPharma, Inc. (NASDAQ: KRBP): (i) pursuant and/or tra...

1 year ago - PRNewsWire

KRBP DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

Radnor, Pennsylvania--(Newsfile Corp. - September 30, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed ...

1 year ago - Newsfile Corp

TUESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - September 30, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioP...

1 year ago - Newsfile Corp